UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Outcome-Based Payment Schemes: What Outcomes Do Patients with Cancer Value?

Lorgelly, P; Pollard, J; Cubi-Molla, P; Cole, A; Sim, D; Sussex, J; (2020) Outcome-Based Payment Schemes: What Outcomes Do Patients with Cancer Value? The Patient - Patient-Centered Outcomes Research 10.1007/s40271-020-00430-x. (In press). Green open access

[thumbnail of Lorgelly2020_Article_Outcome-BasedPaymentSchemesWha.pdf]
Preview
Text
Lorgelly2020_Article_Outcome-BasedPaymentSchemesWha.pdf - Published Version

Download (990kB) | Preview

Abstract

BACKGROUND: Uncertainty about the benefits new cancer medicines will deliver in clinical practice risks delaying patient access to new treatment options in countries such as England, where the cost effectiveness of new medicines affects reimbursement decisions. Outcome-based payment (OBP) schemes, whereby the price paid for the drug is linked to patients' real-world treatment outcome(s) has been put forward as a mechanism to accelerate access. Although OBP schemes have generally focused on clinical outcomes to determine reimbursement, the degree to which these represent the outcomes that are important to patients is unclear. OBJECTIVE: To advance the application of OBP we ask, what outcomes do patients with cancer value (most) that might form a practical basis for OBP? METHODS: A review of the literature on outcomes in cancer produced a long list of candidates. These were evaluated in a focus group with patients with cancer and were then, in a second focus group, distilled to a shortlist of ten outcomes using a card sort method. The ten outcomes were included in an online survey of patients with cancer and carers, who were asked to rank the importance of each outcome. RESULTS: The focus groups identified a range of both clinical and functional outcomes that are important to patients. Analyses of the 164 survey responses suggested that the four most important outcomes to patients and carers are survival; progression, relapse or recurrence; post-treatment side effects; and return to normal activities of daily life. CONCLUSION: Commissioners of cancer services wishing to instigate an OBP scheme should prioritise collecting data on these outcomes as they are important to patients. Of these, only mortality data are routinely collected within the national health service (NHS). Progression and some morbidity data exist but are not currently linked, creating a challenge for OBP.

Type: Article
Title: Outcome-Based Payment Schemes: What Outcomes Do Patients with Cancer Value?
Location: New Zealand
Open access status: An open access version is available from UCL Discovery
DOI: 10.1007/s40271-020-00430-x
Publisher version: https://doi.org/10.1007/s40271-020-00430-x
Language: English
Additional information: © 2020 Springer Nature Switzerland AG. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/).
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health > Applied Health Research
URI: https://discovery.ucl.ac.uk/id/eprint/10106390
Downloads since deposit
107Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item